Harbinger Health launches RESOLVE blood test with $100M to speed cancer diagnosis

What's the deal? Cambridge, Massachusetts-based Harbinger Health has announced RESOLVE, a new category of blood-based multi-cancer detection tests designed to help clinicians move faster from cancer suspicion to diagnosis.

The company simultaneously disclosed that it raised $100 million in 2025 to fund the programme — a round led by Flagship Pioneering, the biotech venture firm that founded Harbinger in 2020, with all existing investors participating.

RESOLVE is aimed at the critical and underserved window between a patient presenting with concerning symptoms and receiving a confirmed cancer diagnosis — a period that currently takes an average of five months, during which mortality can increase by up to 8% for every month of delay in starting treatment.

Why now? Harbinger's pivotal clinical validation study, PROCARES, is approaching full enrolment — more than 88% of participants are enrolled. CEO Ajit SinghDealroom has a profile for this one. Try Dealroom →, who joined in August 2025 from a career in diagnostics commercialisation, expects the first RESOLVE products to be commercially available in the second half of 2026, making this the moment to establish the brand and category ahead of launch

The announcement builds on the completed CORE-HH study, which demonstrated meaningful performance in detecting multiple cancers with a low false-positive rate across cancer types — the scientific foundation for the product's commercial claims.

What could go wrong? The multi-cancer detection space is crowded and increasingly competitive. Grail's Galleri test is already on the market, and Exact Sciences, Illumina, and others are advancing their own blood-based cancer detection programmes.

Harbinger's RESOLVE is positioned differently — targeting the symptomatic window rather than asymptomatic screening — but the clinical evidence bar is high and regulatory pathways for novel diagnostics are long and uncertain.

The PROCARES study is still ongoing, meaning full validation data is not yet available. Commercial launch in the second half of 2026 depends on that data reading out as expected and on securing the necessary regulatory clearances in time.

The signal: Harbinger's launch of RESOLVE as a distinct product category reflects a maturing of the liquid biopsy field — the use of blood tests to detect cancer signals. The market is shifting from early-stage science to commercial differentiation, and companies are now competing not just on technology but on clinical positioning and health system integration.

Harbinger's focus on the symptomatic diagnostic gap is a smart wedge: it is a clearly defined unmet need, it is supported by evidence that delays cost lives, and it does not require the mass population screening infrastructure that asymptomatic tests demand. Whether RESOLVE can establish itself as the standard of care in this window will depend on the PROCARES data — but the category framing is well-constructed.

Sources:
Harbinger Health
PR Newswire
Fierce Biotech
Morningstar
Business Journals

Image credit:
Flagship Pioneering

J.V.